(Q67915613)

English

Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327

scientific article published on 01 January 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Effect of castration, DES, flutamide, and the 5α-reductase inhibitor, MK-906, on the growth of the dunning rat prostatic carcinoma, R-3327 (English)

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

author name string

J. R. Brooks

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

C. Berman

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

H. Nguyen

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

S. Prahalada

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

R. L. Primka

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

G. H. Rasmusson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

E. E. Slater

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1850515

9 December 2022

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1850515

9 December 2022

publication date

1 January 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.2990180304

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

https://onlinelibrary.wiley.com/doi/full/10.1002/pros.2990180304

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

215-227

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Cancer Treatment Reports

2

61

273

author name string

Smolev

publication date

1977

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers.

3

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Kinetic parameters of 5 alpha-reductase activity in stroma and epithelium of normal, hyperplastic, and carcinomatous human prostates.

4

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding

5

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

5 Alpha-reductase inhibitory and anti-androgenic activities of some 4-azasteroids in the rat

6

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors

7

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

8

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Experimental treatment of prostatic cancer by intermittent hormonal therapy

9

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model

10

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer

12

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H)

13

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

New Tables for Multiple Comparisons with a Control

14

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Direct effects of oestradiol on growth and morphology of the Dunning R3327H prostatic carcinoma

16

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Antagonistic action of estrogens, flutamide, and human growth hormone on androgen-induced changes in the activities of some enzymes of hepatic steroid metabolism in the rat

18

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Inhibition of prostatic growth in rats by 6-methylene-4-3,20-dione

20

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone

21

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice

25

1 reference

10.1002/PROS.2990180304

https://api.crossref.org/works/10.1002/PROS.2990180304

9 December 2022

Identifiers

10.1002/PROS.2990180304

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1850515%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q67915613&oldid=1787128841"